[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 109 pages | ID: PBA64FB563CDEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Polycystic Kidney Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Drugs In Development, 2022, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.

Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 18 and 14 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.

Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Polycystic Kidney Disease - Overview
Polycystic Kidney Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Kidney Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Kidney Disease - Companies Involved in Therapeutics Development
Polycystic Kidney Disease - Drug Profiles
Polycystic Kidney Disease - Dormant Projects
Polycystic Kidney Disease - Discontinued Products
Polycystic Kidney Disease - Product Development Milestones
Featured News & Press Releases
Jul 13, 2022: XORTX announces positive topline results from pharmacokinetics bridging clinical trial
Jul 07, 2022: XORTX announces pre-phase 3 meeting request with US Food and Drug Administration (FDA)
Jun 21, 2022: Regulus Therapeutics announces receipt of FDA orphan drug designation for RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
Jun 13, 2022: Regulus Therapeutics announces first subject dosed in phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
May 11, 2022: Regulus Therapeutics announces FDA acceptance of Investigational New Drug (IND) application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 05, 2022: XORTX opens an IND for XRx-008 program for Autosomal Dominant Polycystic Kidney Disease
May 03, 2022: XORTX initiates dosing of human subjects in the XRX-OXY-101 clinical trial
Apr 25, 2022: Poxel announces its participation in upcoming scientific conference of PXL770
Apr 12, 2022: XORTX receives no objection letter from Health Canada
Apr 07, 2022: XORTX announces grant of US patent
Mar 31, 2022: XORTX files IND with US FDA
Mar 14, 2022: XORTX Therapeutics announces submission of clinical trial application to conduct Bridging Pharmacokinetics Study
Jan 20, 2022: Regulus Therapeutics announces successful completion of pre-IND meeting with FDA for RGLS8429
Dec 21, 2021: XORTX Therapeutics announces filing of provision patent for polycystic kidney disease
Dec 01, 2021: Regulus Therapeutics announces presentation at the first annual Rare & Genetic Kidney Disease Drug Development Summit
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Polycystic Kidney Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Polycystic Kidney Disease - Pipeline by AceLink Therapeutics Inc, 2022
Polycystic Kidney Disease - Pipeline by Amathus Therapeutics Inc, 2022
Polycystic Kidney Disease - Pipeline by AmMax Bio Inc, 2022
Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, 2022
Polycystic Kidney Disease - Pipeline by ATLAS Molecular Pharma SL, 2022
Polycystic Kidney Disease - Pipeline by Bristol-Myers Squibb Co, 2022
Polycystic Kidney Disease - Pipeline by Camurus AB, 2022
Polycystic Kidney Disease - Pipeline by Centessa Pharmaceuticals Plc, 2022
Polycystic Kidney Disease - Pipeline by Chimerna Therapeutics Inc, 2022
Polycystic Kidney Disease - Pipeline by Chinook Therapeutics Inc, 2022
Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, 2022
Polycystic Kidney Disease - Pipeline by Eloxx Pharmaceuticals Inc, 2022
Polycystic Kidney Disease - Pipeline by Galapagos NV, 2022
Polycystic Kidney Disease - Pipeline by Generian Pharmaceuticals Inc, 2022
Polycystic Kidney Disease - Pipeline by GLG Pharma SA, 2022
Polycystic Kidney Disease - Pipeline by Goldfinch Bio Inc, 2022
Polycystic Kidney Disease - Pipeline by Healx Ltd, 2022
Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, 2022
Polycystic Kidney Disease - Pipeline by Ipsen SA, 2022
Polycystic Kidney Disease - Pipeline by Johnson & Johnson, 2022
Polycystic Kidney Disease - Pipeline by Kadmon Holdings Inc, 2022
Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, 2022
Polycystic Kidney Disease - Pipeline by Mironid Ltd, 2022
Polycystic Kidney Disease - Pipeline by Mitotherapeutix LLC, 2022
Polycystic Kidney Disease - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Polycystic Kidney Disease - Pipeline by Pano Therapeutics Inc, 2022
Polycystic Kidney Disease - Pipeline by Poxel SA, 2022
Polycystic Kidney Disease - Pipeline by Reata Pharmaceuticals Inc, 2022
Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, 2022
Polycystic Kidney Disease - Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022
Polycystic Kidney Disease - Pipeline by Surrozen Inc, 2022
Polycystic Kidney Disease - Pipeline by XORTX Therapeutics Inc, 2022
Polycystic Kidney Disease - Dormant Projects, 2022
Polycystic Kidney Disease - Dormant Projects, 2022 (Contd..1)
Polycystic Kidney Disease - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Polycystic Kidney Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022


More Publications